-
1
-
-
84928603336
-
European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases
-
Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
-
(2015)
J Crohns Colitis
, vol.9
, pp. 211-222
-
-
Dignass, A.U.1
Gasche, C.2
Bettenworth, D.3
-
2
-
-
85069856223
-
-
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease., Accessed May 22, 2019
-
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2012. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed May 22, 2019.
-
(2012)
-
-
-
3
-
-
38049048044
-
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases
-
Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-1553.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1545-1553
-
-
Gasche, C.1
Berstad, A.2
Befrits, R.3
-
4
-
-
84973130364
-
Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference
-
Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2016;89:28-39.
-
(2016)
Kidney Int
, vol.89
, pp. 28-39
-
-
Macdougall, I.C.1
Bircher, A.J.2
Eckardt, K.U.3
-
5
-
-
85000968659
-
Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron
-
Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45:60-62.
-
(2017)
Am J Nephrol
, vol.45
, pp. 60-62
-
-
Macdougall, I.C.1
Vernon, K.2
-
6
-
-
85001073675
-
Distinct in vitro complement activation by various intravenous iron preparations
-
Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45:49-59.
-
(2017)
Am J Nephrol
, vol.45
, pp. 49-59
-
-
Hempel, J.C.1
Poppelaars, F.2
Gaya da Costa, M.3
-
7
-
-
84908459097
-
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
-
Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671-1676.
-
(2014)
Haematologica
, vol.99
, pp. 1671-1676
-
-
Rampton, D.1
Folkersen, J.2
Fishbane, S.3
-
8
-
-
34247615981
-
Clinical update: intravenous iron for anaemia
-
Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502-1504.
-
(2007)
Lancet
, vol.369
, pp. 1502-1504
-
-
Auerbach, M.1
Ballard, H.2
Glaspy, J.3
-
9
-
-
85031284867
-
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose for the treatment of iron deficiency anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
-
Adkinson NF, Strauss WE, Bernard K, Kaper RF, Macdougall IC, Krop JS. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose for the treatment of iron deficiency anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. J Blood Med. 2017;8:155-163.
-
(2017)
J Blood Med
, vol.8
, pp. 155-163
-
-
Adkinson, N.F.1
Strauss, W.E.2
Bernard, K.3
Kaper, R.F.4
Macdougall, I.C.5
Krop, J.S.6
-
10
-
-
85042412026
-
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial
-
Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683-690.
-
(2018)
Am J Hematol
, vol.93
, pp. 683-690
-
-
Adkinson, N.F.1
Strauss, W.E.2
Macdougall, I.C.3
-
11
-
-
85059183416
-
Iron therapy in heart failure: ready for primetime
-
Mordi IR, Tee A, Lang CC. Iron therapy in heart failure: ready for primetime. Card Fail Rev. 2018;4:28-32.
-
(2018)
Card Fail Rev
, vol.4
, pp. 28-32
-
-
Mordi, I.R.1
Tee, A.2
Lang, C.C.3
-
12
-
-
79960617268
-
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications
-
Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480-491.
-
(2011)
Eur J Pharm Biopharm
, vol.78
, pp. 480-491
-
-
Jahn, M.R.1
Andreasen, H.B.2
Futterer, S.3
-
13
-
-
77951634849
-
Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury
-
Haase M, Bellomo R, Haase-Fielitz A. Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol. 2010;55:2024-2033.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2024-2033
-
-
Haase, M.1
Bellomo, R.2
Haase-Fielitz, A.3
-
14
-
-
85011614591
-
Reactive oxygen species: a key hallmark of cardiovascular disease
-
Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med. 2016;2016:9152732.
-
(2016)
Adv Med
, vol.2016
, pp. 9152732
-
-
Panth, N.1
Paudel, K.R.2
Parajuli, K.3
-
15
-
-
79953284567
-
Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study
-
Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11:131-137.
-
(2010)
Transfus Altern Transfus Med
, vol.11
, pp. 131-137
-
-
Hildebrandt, P.R.1
Bruun, N.E.2
Nielsen, O.W.3
-
16
-
-
79958169242
-
Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease
-
Wikstrom B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589-596.
-
(2011)
J Nephrol
, vol.24
, pp. 589-596
-
-
Wikstrom, B.1
Bhandari, S.2
Barany, P.3
-
17
-
-
84937150491
-
A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
-
Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226-1233.
-
(2015)
Scand J Gastroenterol
, vol.50
, pp. 1226-1233
-
-
Reinisch, W.1
Altorjay, I.2
Zsigmond, F.3
-
18
-
-
84889690772
-
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
-
Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877-1888.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 1877-1888
-
-
Reinisch, W.1
Staun, M.2
Tandon, R.K.3
-
19
-
-
84941598898
-
Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)
-
Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109:257-266.
-
(2015)
Vox Sang
, vol.109
, pp. 257-266
-
-
Johansson, P.I.1
Rasmussen, A.S.2
Thomsen, L.L.3
-
20
-
-
84940645637
-
A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients
-
Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577-1589.
-
(2015)
Nephrol Dial Transplant
, vol.30
, pp. 1577-1589
-
-
Bhandari, S.1
Kalra, P.A.2
Kothari, J.3
-
21
-
-
84965179566
-
A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
-
Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646-655.
-
(2016)
Nephrol Dial Transplant
, vol.31
, pp. 646-655
-
-
Kalra, P.A.1
Bhandari, S.2
Saxena, S.3
-
22
-
-
84963682363
-
A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy, the profound trial
-
Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy, the profound trial. Pharmacotherapy. 2016;36:402-414.
-
(2016)
Pharmacotherapy
, vol.36
, pp. 402-414
-
-
Birgegard, G.1
Henry, D.2
Glaspy, J.3
Chopra, R.4
Thomsen, L.L.5
Auerbach, M.6
-
23
-
-
84975266509
-
High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
-
Dahlerup JF, Jacobsen BA, van der Woude J, Bark LA, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332-1338.
-
(2016)
Scand J Gastroenterol
, vol.51
, pp. 1332-1338
-
-
Dahlerup, J.F.1
Jacobsen, B.A.2
van der Woude, J.3
Bark, L.A.4
Thomsen, L.L.5
Lindgren, S.6
-
24
-
-
85013158265
-
Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial
-
Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;112:219-228.
-
(2017)
Vox Sang
, vol.112
, pp. 219-228
-
-
Holm, C.1
Thomsen, L.L.2
Norgaard, A.3
Langhoff-Roos, J.4
-
25
-
-
85007426093
-
Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study
-
Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang. 2017;112:122-131.
-
(2017)
Vox Sang
, vol.112
, pp. 122-131
-
-
Holm, C.1
Thomsen, L.L.2
Norgaard, A.3
Langhoff-Roos, J.4
-
26
-
-
85041515292
-
Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial
-
Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion. 2018;58:974-981.
-
(2018)
Transfusion
, vol.58
, pp. 974-981
-
-
Gybel-Brask, M.1
Seeberg, J.2
Thomsen, L.L.3
Johansson, P.I.4
-
27
-
-
85011025181
-
A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
-
Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286-291.
-
(2017)
Am J Hematol
, vol.92
, pp. 286-291
-
-
Derman, R.1
Roman, E.2
Modiano, M.R.3
Achebe, M.M.4
Thomsen, L.L.5
Auerbach, M.6
-
28
-
-
85070423381
-
-
July 21, Food and Drug Administration, Accessed May 22, 2019
-
Medical review of ferric carboxymaltose, application number 203565Orig1s000, Center for Drug Evaluation and Research, Food and Drug Administration, July 21, 2013. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000MedR.pdf. Accessed May 22, 2019
-
(2013)
Medical Review of Ferric Carboxymaltose, Application Number 203565Orig1s000, Center for Drug Evaluation and Research, Food and Drug Administration
-
-
-
29
-
-
84947431101
-
Comparative risk of anaphylactic reactions associated with intravenous iron products
-
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062-2068.
-
(2015)
JAMA
, vol.314
, pp. 2062-2068
-
-
Wang, C.1
Graham, D.J.2
Kane, R.C.3
-
30
-
-
84983311761
-
Safety of intravenous iron use in chronic kidney disease
-
Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529-535.
-
(2016)
Curr Opin Nephrol Hypertens
, vol.25
, pp. 529-535
-
-
Kalra, P.A.1
Bhandari, S.2
-
31
-
-
84961176944
-
Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia
-
Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53-64.
-
(2016)
Int J Nephrol Renovasc Dis
, vol.9
, pp. 53-64
-
-
Kalra, P.A.1
Bhandari, S.2
-
32
-
-
85044230148
-
Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage
-
Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med. 2019;32:2797-2804.
-
(2019)
J Matern Fetal Neonatal Med
, vol.32
, pp. 2797-2804
-
-
Holm, C.1
Thomsen, L.L.2
Langhoff-Roos, J.3
|